comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 01:37:09 - browse：198

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： New Alzheimer's drugs heat up race for early detection blood tests

entertainment

WSS

Why patients can’t get everything they want on drug pricing

Dems pitch expanding Medicare power to negotiate drug prices

Death of patient in Alzheimer’s trial raises question of possible risks

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

What causes rare myocarditis in young men after Covid vaccines?

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

comprehensive

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Paxlovid study fails to answer questions over benefit for broader groups

Guidelines to prevent youth baseball injuries need more muscle

Weight bias in eating disorder treatment complicated by new weight loss drugs

Bright Health sells Medicare Advantage business to Molina

UHS says company favors patients whose insurance pays more

Hepatitis C has a cure — but many Americans still lack access to it

Senate panel puts off hardest PBM reforms for another day

Duchenne breakthrough therapy leaves behind pioneering families

Democrats decry new health bill for going easy on private equity

knowledge

Disclosing genetic information: not as worrisome as once feared

Truvian presents data for its desktop blood

Colonoscopy at 40? Study finds a possible benefit

3 hurdles to bringing medical devices to the U.S. market

Colonoscopy at 40? Study finds a possible benefit

Dems pitch expanding Medicare power to negotiate drug prices

entertainment

hotspot

explore

leisure time